

1 **Association between virtual visits and health outcomes of people living with HIV: A cross-sectional**
2 **study**

3
4 Nadia Rehman^{1*}, Lawrence Mbuagbaw^{1,2,3,4,5,6}, Dominik Mertz^{1,7,8¶}, Giulia M. Muraca^{1,9¶}, on behalf of
5 the Ontario HIV Treatment Network Cohort Study[^] and Realize[^], Aaron Jones^{1,10,11}

6
7 ¹Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario,
8 Canada

9 ²Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada

10 ³Centre for Development of Best Practices in Health (CDBPH), Yaoundé Central Hospital, Yaoundé,
11 Cameroon

12 ⁴Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

13 ⁵Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, Ontario,
14 Canada

15 ⁶Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape
16 Town, South Africa

17 ⁷Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

18 ⁸Department of Medicine, McMaster University, Hamilton, Ontario, Canada

19 ⁹Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada

20 ¹⁰Institute for Clinical Evaluative Sciences (IC/ES), McMaster University, Hamilton, Ontario, Canada

21 ¹¹Institute for Clinical Evaluative Sciences; IC/ES, University of Toronto, Ontario, Canada

22

23

24 ***Corresponding Author**

25 Email: rehmann@mcmaster.ca (NR)

26

27 ¶ These authors contributed equally to this work.

28

29 ^ Membership of the Ontario HIV Treatment Network (OHTN) is provided in the Acknowledgments.

30 ^ Member of Realize is provided in the Acknowledgments.

31

32 **Abstract**

33 **Background:** Virtual care has been integrated as a modality of care in Ontario, yet its effectiveness for
34 people living with HIV remains largely unexplored.

35 **Objectives:** We aimed to determine the association of visit modality (virtual, in-person, or both) on
36 adherence to antiretroviral therapy (ART), viral load, and quality of life (QOL) in people living with HIV
37 in Ontario, Canada.

38 **Methods:** We conducted a cross-sectional study using data from the 2022 Ontario HIV Treatment
39 Network Cohort Study (OCS), collected during the COVID-19 pandemic when virtual visits were first
40 introduced. Participants were grouped into three categories based on the mode of care: virtual, in-person,
41 or a combination of both. Data were collected through self-reported questionnaires and medical records,
42 with viral load data linked to Public Health Ontario Laboratories (PHOL). Logistic regression was used to
43 examine the outcomes of optimal ART adherence and viral load suppression, and linear regression was
44 used for quality of life (mental and physical) outcomes.

45 **Results:** In 2022, 1930 participants accessed HIV care in the OCS. Among them, 19.0% received virtual
46 care, 45.6% received in-person care, and 34.3% received care through virtual and in-person modalities. The
47 median age of the participants was 55 years (IQR: 45-62). In the multivariable logistic regression model,
48 virtual care was associated with an increased likelihood of optimal adherence to antiretroviral therapy
49 (Adjusted Odds Ratio (AOR) 1.30, 95% confidence interval (CI): 1.00-1.70) and an increased likelihood
50 of achieving viral load suppression (AOR 1.67, 95% CI:1.03-2.63). Moreover, combined virtual and in-
51 person care is associated with an improved mental quality of life compared to in-person care (Adjusted
52 Mean difference (MD) - 0.960, 95% CI 0.052,1.869).

53 **Conclusion:** This study suggests virtual care is positively associated with adherence to antiretroviral
54 therapy (ART) and viral suppression within this context. However, future research is necessary to establish
55 causality and to assess the long-term effects of virtual care.

56 **Word count:** 2790

58 Introduction

59 HIV is a chronic health challenge, with 22,461 people living with HIV in Ontario, Canada, as of
60 2020 [1]. This population faces a disproportionate burden due to socio-economic disparities and structural
61 barriers within the patient-provider relationship, which further complicates the continuity of HIV care,
62 contributing to sub-optimal retention in healthcare services and poor adherence to antiretroviral therapy
63 (ART) [2]. This results in detectable viral loads, increased opportunistic infections, and higher morbidity
64 and mortality rates [3-6]. Consistent access to ART and regular health assessments necessitates strong
65 patient retention in care, as highlighted by several studies [7-9]. Despite universal public coverage in
66 Ontario, challenges with retaining individuals in care persist. A fully accessible, patient-centred healthcare
67 system is essential to addressing these issues [10].

68 In 2021, Ontario, Canada, adopted virtual care in the healthcare sector to help mitigate the impact
69 of the SARS-CoV-2 pandemic [12]. Virtual care is a health care model in which all clinical interactions
70 between the practitioner and the patient are delivered using electronic mediums, such as video conferencing
71 or audio digital tools, such as telephone [11]. Since 2022, Ontario has taken concrete measures to integrate
72 virtual visits as complementary to traditional care. These measures include enhancing data security and
73 privacy, addressing social and ethical considerations, establishing regulations for virtual healthcare, and
74 introducing fee codes that enable physicians to bill for virtual visits [10, 12].

75 Virtual visits can help overcome barriers in HIV care by offering convenience, accessibility, and
76 affordability, potentially improving access to care and patient retention [13, 14]. However, virtual care has
77 several limitations, such as the inability to assess clinical conditions objectively, the lack of necessary
78 equipment, and the absence of physical interactions with physicians, which can lead to mistrust, multiple
79 appointments, and potential misdiagnosis [13]. Technology can also pose barriers for certain groups,
80 including older adults, individuals with lower literacy levels, and those from disadvantaged socio-economic
81 backgrounds [14]. The choice of virtual care compared to in-person visits may be influenced by physician
82 preferences and the significant discrepancies in Ontario's fee codes between comprehensive versus limited

83 care and telephone calls versus video visits [10, 15]. While some data suggest virtual care improves
84 retention in care, others report increased loss to follow-up [16]. As virtual care evolves, it is essential to
85 address disparities, prevent overuse, and consider unintended financial consequences with health equity
86 and ethical considerations in mind [10, 11, 16-18].

87 While virtual care has become a standard practice in Ontario [10], the evidence of its effectiveness
88 remains limited. We developed this study alongside the Ontario HIV Treatment Network (OHTN) [19],
89 utilizing the data from the Ontario HIV Treatment Network Cohort Study (OCS), the largest community-
90 governed HIV cohort in North America [20]. The primary objective of the study was to assess whether
91 there were differences in adherence to antiretroviral therapy (ART), quality of life (QOL), and viral load
92 among people living with HIV in Ontario, Canada, based on whether they used virtual or in-person
93 appointments with an HIV care physician. The secondary objective of the study was to evaluate the
94 differences in health outcomes (adherence to ART, QOL, and viral load) among people living with HIV
95 from various socio-demographic and health-related factors in Ontario, as virtual care may affect certain
96 groups differently.

97 **Methods**

98 **Study Design**

99 We conducted a cross-sectional study using data from participants in the OCS in 2022.

100 **Setting**

101 The OCS is a multi-site clinical cohort of people receiving HIV care in Ontario, Canada's most
102 populous province (population: 13.6 million). Recruitment occurs at ten participating sites, including
103 outpatient clinics in hospitals and community-based practices. The cohort has been described elsewhere
104 [21].

105 **Stakeholder Engagement**

106 To achieve our study objectives, we established a community advisory board (CAB) in
107 collaboration with Realize, a Canadian charitable organization working with people living with HIV and
108 related organizations. The CAB comprises representatives from various key populations of people living
109 with HIV, enhancing the external validity of our project, bolstering individual and community capacity,
110 and ensuring the effective implementation of our research findings [22, 23]. We convened a meeting with
111 the CAB to seek their insights on the relevance of the research question, the socio-demographic factors
112 involved, and the correlation with the health conditions of people living with HIV. The CAB also actively
113 interpreted the findings and collaborated on a dissemination plan for our research outcomes.

114 **Data Sources**

115 Clinical data are collected during routine follow-up visits, sourced from clinic records via manual
116 chart abstractions or computerized medical record systems, and record linkage with Public Health Ontario
117 Laboratories (PHOL), the sole provider of such testing provincially. Additionally, annual interviews are
118 conducted using standardized questionnaires to gather socio-demographic and psycho-social-behavioural
119 information. All participants provide written informed consent, and the cohort design and consent forms
120 are approved by the University of Toronto Research Ethics Boards (REBs) and REBs at each participating
121 site [21]. Data was accessed on November 23, 2023. And the data was in de-identified form.

122 **Population**

123 Eligible participants for our study are those aged 16 years or older who visited their HIV physician
124 using any of the three modalities of care (virtual, in-person visits, or both virtual and in-person care) in
125 2022 and completed the OCS questionnaire. Participants with incomplete information on the type of care
126 received were excluded.

127 **Measures/Outcomes**

128 **Primary outcome**

129 Adherence to ART was assessed using self-reported data from the standardized OCS questionnaire.
130 For this study, we aimed to dichotomize adherence into optimal adherence ($\geq 95\%$) and suboptimal
131 adherence ($< 95\%$). We considered optimal adherence as participants who reported never missing a dose or
132 missing a dose more than three months ago. In contrast, suboptimal adherence included those who missed
133 doses within the past week, 1–4 weeks ago, 1-3 months, or responded with "don't know." These
134 classifications were established in consultation with HIV specialists from a dedicated HIV care facility.

135 **Secondary Outcomes**

136 Viral load suppression was defined as ≤ 40 copies/mL, indicating virological suppression (stable
137 viral load). Any value > 40 copies/mL is considered virologically unsuppressed and unfavourable. QOL
138 was assessed using the Short Form 12-item Health Survey (version 2), which includes two components: the
139 Mental Component Summary Score (MCS) and the Physical Component Summary Score (PCS), both of
140 which are reported separately [24].

141 **Variables**

142 **Primary exposure**

143 We categorized the HIV care that the patients received into three mutually exclusive categories: i).
144 In-person care at the clinic ii). Virtual care either by telephone or video call, iii). Combination of in-person
145 and virtual forms of care.

146 **Demographic and clinical variables**

147 Baseline demographic and clinical data were extracted from the 2022 OCS questionnaire. Due to
148 multiple categories in the OCS data, some of which were not information-rich, we consolidated them into
149 meaningful categories for our study. Data missing values are reported separately in Table 1, which details
150 the baseline characteristics.

151 For demographic variables, we combined sex (female versus male) and sexual orientation (men
152 who have sex with men (MSM) vs non-MSM) to derive a single variable named sex, comprising three
153 categories: females, male MSM, and male non-MSM and relationship status categorized as stable (married,
154 living common-law, living in a committed relationship) vs unstable relationship (widowed,
155 separated/divorced, single).

156 Clinical variables were extracted on the following health conditions: alcohol use disorder syndrome
157 use was defined as on the Alcohol Use Disorder Identification Test (AUDIT-10) with harmful alcohol
158 measured from 10- items (a score of ≥ 8 regardless of gender/sex) [25], depression measured by the Patient
159 Health Questionnaire (PHQ) scale with nine items [26], smoking cigarettes/tobacco defined as heavy
160 smokers versus light smokers (heavy smokers defined as people who have been smoking at least 20
161 cigarettes daily) [27]; and diagnosis of mental health comorbidities was based on self-report in the OCS
162 question.

163 We used a revised 10-item HIV-related stigma scale categorized into four major components of
164 HIV-related stigma: personalized stigma, worries about disclosure of status, negative self-image, and
165 sensitivity to public reactions about HIV status. Individuals who responded with “agree” and “strongly
166 agree” were identified as experiencing stigma in at least one of the four components [28].

167 **Sample size calculations:**

168 The study was planned with a sample size of 1,930 subjects, providing 80% power to detect a
169 difference of 20% or greater between suboptimal and optimal adherence to ART between the groups. [29].
170 The Type I error probability associated with the test of the null hypothesis is 0.05 for the two-tailed chi-

171 squared statistic. (PS: Power and Sample Size Calculation version 3.1.2, 2014 by W.D. Dupont & W.D.
172 Plummer Jr).

173 **Data analysis:**

174 Statistical analysis was performed using R software version 4.4.1. We used descriptive statistics to
175 analyze participants' characteristics, reporting proportions for categorical variables and median with
176 interquartile range (IQR) for continuous variables. The latter were compared using the Wilcoxon rank-sum
177 test, as these scores are not normally distributed [30]. Chi-square tests were used for categorical variables.

178 The variable selection was guided by a priori knowledge of their association with adherence to
179 ART, considering collinearity between variables and potential confounding. Age, sex, ethnicity,
180 employment, education level, substance use, stigma and living alone were included in all models as
181 potential confounders, regardless of their significance [3, 11, 31, 32]. To select the remaining variables for
182 our models, we used the 'majority selection method' and selected the variables that appeared in at least half
183 of the models [33]

184 **Regression Analysis:**

185 We conducted a logistic regression analysis for dichotomous outcomes (adherence to ART and
186 suppression of the viral load) and a multiple linear regression for continuous outcomes (quality of life). To
187 check the model fit for multiple linear regression models, we used a pooled R^2 . The dichotomous outcomes
188 are reported as odds ratio (OR) and 95% confidence intervals, and continuous outcomes are reported as
189 mean differences with 95% confidence intervals. The statistically significant level is set when the p -value
190 is <0.05 or the 95% CI excludes the null value.

191 The OCS questionnaire had data missing at random (MAR), so we performed ten imputations for
192 each model and combined the results using Rubin's rules [33, 34].

193 **Subgroup analysis**

194 We performed subgroup analysis to assess the differences in health outcomes (adherence to ART,
195 quality of life and viral load) of people living with HIV from different socio-demographics in Ontario,
196 Canada. The data from the OCS Questionnaire 2022 was collected during the COVID-19 pandemic when
197 virtual visits were first introduced. [15]. Since government COVID-19 policies and users' preferences may
198 have impacted decisions to attend virtual visits, we compared outcomes during and after lockdowns [35].

199 Results

200 In 2022, the OCS questionnaire was completed by 2155 people, with 1930 providing details on the
201 type of care they received (S 1 Fig). That year, 1021/1930 (53%) HIV care visits were conducted by
202 telephone, 23/1930 (1.2%) via computer visits, and 1563/1930 (80%) were provided through in-person
203 visits. The median age of the participants was 55 years [IQR: 45-62]. In 2022, stratum-specific proportions
204 of participants in the three different types of care modalities (i.e. in-person, virtual and participants who
205 used both in-person and virtual care) varied by participant characteristics (Table 1). Notably, 1493/1930
206 (78%) participants were men, with the majority being MSM, comprising 58.6% (1131/1930). Regarding
207 care modality preferences, in-person visits were most preferred across all genders. Table 1 provides the
208 statistical relationship between all other variables and the type of care.

Table 1. Comparison of baseline characteristics between participants who accessed HIV care through virtual, in-person or both virtual and in-person care in Ontario, Canada, in 2022

Characteristics	In-person care n (%)	Virtual care n (%)	Virtual and in- person care n (%)	p-value
No. of participants	900	367	663	
<i>Median age [Q1-Q3]</i>	55 [44-63]	56 [46-62]	55 [45-62]	0.772
<i>Sex</i>				

Female	233 (25.9)	60 (16.3)	132 (20.2)	<0.001
Male MSM ^a	459 (50.8)	253 (70.0)	419 (63.4)	
Male non-MSM	203 (22.6)	49 (13.4)	110 (16.2)	
Missing	5 (0.55)	5 (1)	2 (0.3)	
<i>Race</i>				
White	478 (53.1)	252 (68.7)	442 (66.6)	< 0.001
Black	263 (29.3)	55 (14.9)	130 (19.6)	
Other	159 (17.6)	60 (16.3)	91 (13.7)	
<i>Region</i>				
Eastern Ontario	127 (14.1)	24 (6.5)	22 (3.3)	< 0.001
Northern Ontario	18 (2)	5 (1.4)	2 (0.3)	
Southwestern Ontario	99 (11)	62 (16.9)	174 (26.2)	
Toronto	656 (72.8)	276 (75.2)	465 (70.1)	
<i>Education</i>				
Elementary	25 (2.7)	10 (2.7)	14 (2.1)	0.246
High school	239 (26.5)	126 (34.3)	224 (33.7)	
College	210 (23.3)	64 (17.4)	139 (20.9)	
Higher education	363 (40.3)	162 (44.1)	284 (42.8)	
Missing	63 (7)	5 (1.4)	2 (0.3)	
<i>Employment status</i>				
Employed	433 (48.1)	182 (49.6)	327 (49.3)	0.285
Unemployed	463 (51.4)	182 (49.6)	336 (50.7)	
Missing	4 (0.4)	3 (0.8)	0 (0)	
<i>Gross annual income</i>				
<50,000	374 (41.5)	144 (39.2)	280 (42.2)	0.287

< 50,000-70,000	103(11.4)	45 (12.2)	75 (11.3)	
< 70,000-80,000	121 (13.4)	41 (11.1)	76 (11.4)	
>100,000	173 (19.2)	94 (25.6)	150 (22.6)	
Missing	129 (14.3)	43 (11.7)	82 (12.3)	
<i>Stable relationship</i>				
Yes	376 (41.6)	154 (42.0)	246 (37.1)	0.17
Unstable relationship	521 (57.8)	212 (57.8)	417 (62.9)	
Missing	3 (0.3)	1 (0.3)	0 (0)	
<i>Adherence to ART</i>				
< 95%	295 (32.7)	137 (37.3)	247 (37.3)	0.014
≥ 95%	600 (66.6)	225 (61.3)	412 (62.1)	
Missing	5 (0.5)	5 (1.3)	4 (0.6)	
<i>Mental health conditions</i>				
Depression	197 (21.8)	44 (12.0)	167 (25.1)	0.190
Alcohol use disorder syndrome ^d	67 (7.4)	34 (9.2)	65 (9.8)	
No	824 (91.6)	331 (90.1)	598 (90.1)	0.248
Yes				
<i>Stigma</i>				
Stigmatized	125 (13.8)	12 (3.28)	92 (13.8)	0.5083
Not stigmatized	8 (0.88)	2 (0.54)	7 (1.05)	
Missing	767 (85.2)	353 (96.1)	564 (85.0)	
<i>Quality of life</i>				
MCS	50.2 [41.25; 57.00]	49.2 [40.82;55.32]	50.9 [38.67;56.30]	0.403

PCS	53.1 [43.8;57.2]	53.5 [44.87;57.35]	52.7 [43.57;56.70]	0.548
<i>Viral load</i>				
≤ 40	766 (85.0)	336 (91.6)	579 (87.3)	0.02
> 40	104 (11.5)	26 (7.0)	70 (10.5)	
Missing	30 (0.5)	5 (1.4)	14 (2.1)	
^a Men who report having sex with other men ^b Immigrant > 10 years ^c Immigrant <10 years ^d Alcohol Use Disorder Identification Test (AUDIT-10)				

209

210 **Adherence to ART**

211 There were 600 (66.6%) participants with optimal ART adherence. According to our logistic
 212 regression analysis, the odds of adherence to ART were higher for participants who used virtual care than
 213 in-person care in both adjusted and unadjusted analysis (OR 1.47 %, 95% CI 1.14, 1.89; AOR 1.31%,
 214 95% CI 1.00-1.71).

215 **Viral load**

216 There were 766 (85.0%) participants with adequate viral load suppression. The odds of viral load
 217 suppression were higher in the virtual group than in person-care (OR 1.81, 95%CI: 0.69-2.85; AOR 1.67,
 218 95% CI:1.03-2.63).

219 **Quality of life**

220 The average MCS score was 50.2 and, the average PCS score was 53.1. According to our
 221 adjusted multiple regression model, combined virtual and in-person care is associated with an improved
 222 quality of life in terms of MCS compared to in-person care (Mean difference (MD) -0.90, 95 % CI -
 223 2.10,0.30; adjusted MD 0.960, 95% CI 0.052,1.869). All results can be found in Table 2.

224

Table 2: Multivariable regression analysis of HIV-related outcomes of people receiving care in Ontario, Canada				
Variable	Unadjusted Effect Estimates (95%CI)	p-value	Adjusted Effect Estimates (95% CI)	p-value
<i>Adherence to ART (OR)</i>				
In-person(ref)	1.00 (ref)		1.00 (ref)	
Virtual and in-person	1.23 (0.99, 1.52)	0.05	1.03 (0.82, 1.30)	0.743
Virtual	1.47 (1.14, 1.89) *	0.003	1.30 (1.00, 1.70) *	0.048
<i>Viral load (OR) <40 ml/cc preferred</i>				
In-person(ref)	1.00 (ref)		1.00 (ref)	
Virtual and in-person care	1.13 (0.52, 1.56)	0.431	1.08 (0.76, 1.53)	0.651
Virtual care	1.81 (0.69, 2.85)	0.010	1.67 (1.03, 2.63)	0.0374
¹MCS				
In-person visit	0 (ref)		0 (ref)	
Virtual and in-person	-0.90 (-2.10,0.30)	0.142	0.96 (0.05,1.86) *	0.038
Virtual	-0.53 (-1.99, 0.92)	0.469	0.13 (-0.94, 1.2)	0.810
²PCS				
In-person visit	0 (ref)		0 (ref)	
Virtual and in-person	-0.90 (-2.10, 0.30)	0.142	-0.91 (-1.24,0.85)	0.711
Virtual	-0.53 (-1.99, 0.92)	0.469	0.09 (-1.14,1.32)	0.811
<p>^a Adjusted for covariates</p> <p>* Statistically significant</p> <p>¹ Mental Component Summary Score</p> <p>² Physical Component Summary Score</p>				

226 **Sub-group analysis**

227 Among patients whose physicians based their preference of the type of care mode on the viral load,
228 receiving in-person care was associated with lower odds of adherence to ART than receiving virtual care
229 (OR 0.29, 95% CI 0.10-0.83; AOR 0.28, 95% CI 0.09-0.86).

230 Among patients whose physicians based their preference of the type of care mode on the viral load,
231 the receipt of both virtual and in-person care was associated with decreased MCS quality of life compared
232 with participants who used the in-person care mode. (MD -5.60, 95% CI -9.46 - 1.75; Adjusted MD -3.75,
233 95% CI -6.51—0.99). Detailed findings are provided in S 1 Table.

234 **Discussion**

235 This study examined three types of care used in the OCS cohort 2022: in-person, virtual and
236 patients using both. Patients across all demographic and medical backgrounds used virtual care options. In
237 this cohort, the participants who used virtual care mode most frequently were 51-60, perhaps suggesting
238 that older patients are comfortable with technology. However, the predominant mode of care within this
239 cohort remained in-person visits. In this cohort consisting of participants living with HIV in Ontario, we
240 observed that participants with better adherence to ART and with viral load suppression preferred the virtual
241 care, and participants with a higher MCS quality of life utilized both virtual and in-person care.

242 Sex was the strongest predictor of the type of care used, with male MSM favouring in-person care.
243 Participants residing in Toronto preferred virtual care compared to those in Eastern Ontario, though these
244 groups overlap, as many male MSM in Toronto might be the same individuals. Participants with any form
245 of depression tended to use both virtual and in-person care, possibly choosing their care mode based on the
246 severity of their depression at the time of the visit.

247 Our subgroup analysis based on physicians' preference for the type of visit by viral load revealed
248 decreased ART adherence within the virtual care group. However, the primary analysis showed a 30%
249 improvement in ART adherence among participants using virtual visits compared to in-person groups. This

250 suggests physicians preferred in-person visits for patients with unsuppressed viral loads and poor ART
251 adherence.

252 This study has several limitations that prevent drawing definitive conclusions. The cross-sectional
253 design prevents us from establishing causality, making it difficult to determine whether virtual care directly
254 influences HIV related-health outcomes. Additionally, the data analyzed is from 2022, a period when virtual
255 care was newly introduced and still in the early stages of implementation, including the development of
256 specific standards, equipment selection and user training [38, 49]. Moreover, during the study period,
257 decisions regarding the type of care were often influenced by the government's lockdown orders rather than
258 the preferences of physicians or patients [38]. Non-response bias further restricts the conclusion of
259 differences between care modes. Furthermore, challenges related to optimizing virtual care usability and
260 user-friendliness remain unexplored.

261 The OCS employs a standardized questionnaire developed in consultation with the OHTN, CAB
262 and the governance committees. However, the primary outcome—ART adherence—is based on self-
263 reporting, which is subjective and prone to recall bias [3].

264 The study's findings are influenced by selection and information biases, as participants are
265 predominantly aged 51-55, with high incomes and stable housing. This limits the understanding of age-
266 related acceptance and barriers. The cohort mainly includes highly engaged individuals, which doesn't fully
267 represent overall care engagement. Younger, tech-savvy individuals and rural populations are
268 underrepresented in this cohort, limiting insights into the broader applicability of virtual care and rural-
269 urban differences [32, 35].

270 Despite potential sample biases, the study's large sample size and real-time data collection enhance
271 the robustness of its findings.

272 The study was guided by a CAB, whose input was integrated throughout the study, including their
273 feedback on result interpretation. Collaborating closely with experienced HIV care physicians provides

274 valuable insights into clinical practice dynamics and potential implementation strategies based on study
275 outcomes [36].

276 **Future research**

277 It's essential to recognize that this research is exploratory, and the COVID-19 pandemic
278 lockdowns confound it. Future research should explore the impact of virtual visits on HIV care and improve
279 access. Key issues include standards, licensure, equity, and payment systems. Virtual visits can help address
280 physician shortages, especially in rural areas, by offering flexible, quality care. Expanding virtual care to
281 all socioeconomic groups is vital. Redesigning care based on necessity and feasibility could enhance access
282 and outcomes [37, 38]. Future studies should assess system-wide effects, user satisfaction, cost-
283 effectiveness, and physician views while linking OCS data with ICES data to analyze clinical outcomes
284 and patient preferences.

285 **Conclusion**

286 In our study in the OCS 2022 of people living with HIV, participants with better self-reported
287 adherence to ART and a suppressed viral load preferred virtual care as compared to in-person care.
288 Moreover, participants who used both virtual and in-person care reported higher mental health quality of
289 life.

290 **Data Statement**

291 The data is obtained from OHTN from the OCS study. It is unethical for the authors to share the data set
292 publicly. However, the data request can be made directly with OHTN by submitting a [Research Application](#)
293 [Process \(RAP\)](#).

294 **Declaration of Conflicting Interests**

295 The author(s) declared no potential conflicts of interest.

296 **Funding**

297 This study did not receive any funding.

298 **Authors' contributions**

299 A.J., L.M., and N.R. contributed to the study's concept. The study design was finalized after feedback from
300 all the authors (L.M., N.R., M.G., D.M., and A.J.). OHTN provided the final approval and the data. N.R.
301 and A.J. conducted the analysis. N.R. prepared the original draft. All authors critically revised, approved
302 and agreed to be held accountable for all aspects of this work. Realize provided support and guidance for
303 CAB recruitment, consultation on community engagement and study design.

304

305 **Acknowledgements**

306 The OHTN Cohort Study Team consists of Dr. Ann Burchell (Interim Principal Investigator), St. Michael's
307 Hospital and University of Toronto; Dr. Anita Benoit (Co-investigator), University of Toronto; Dr.
308 Lawrence Mbuagbaw (Co-Investigator), McMaster University; Dr. Sergio Rueda, CAMH and University
309 of Toronto; Dr. Gordon Arbess, St. Michael's Hospital; Dr. Jeffrey Cohen, Windsor Regional Hospital; Dr.
310 Curtis Cooper, Ottawa General Hospital; Dr. Maheen Saeed, University of Ottawa Health Services; Dr.
311 Mona Loutfy, Maple Leaf Medical Clinic; Dr. David Knox, Maple Leaf Medical Clinic; Dr. Nisha Andany,
312 Sunnybrook Health Sciences Centre; Dr. Sharon Walmsley, Toronto General Hospital; Dr. Michael
313 Silverman, St. Joseph's Health Care; Ms. Tammy Bourque, Health Sciences North; Wangari Tharao,
314 Women's Health in Women's Hands Community Health Centre; Holly Gauvin, Elevate NWO; Dr. Jeffrey
315 Craig, Lakeridge Health, Dr. Jorge Martinez-Cajas, Kingston Health Sciences Centre, and Dr. Marek
316 Smijea, Hamilton Health Sciences Centre.

317 We gratefully acknowledge all of the people living with HIV who volunteered to participate in the OHTN
318 Cohort Study and the work and support of the OCS Governance Committee: (Dane Record, Jasmine
319 Cotnam, Barry Adam, Adrian Betts, Cornel Gray, Ruth Cameron, Rodney Rousseau, Mary Ndung'u,
320 Viviana Santibañez, YY Chen, Jason Brophy, Aaron Bowerman), OCS Scientific Steering Committee (Dr.
321 Sergio Rueda, Dr. Barry Adam, Dr. David Brennan, Dr. Trevor Hart, Dr. Lance McReady, Dr. Lawrence
322 Mbuagbaw, Dr. Anita Benoit, Dr. Mona Loutfy, Dr. Curtis Cooper, Dr. Sean Hillier, Mr. Pierre Giguere,
323 Dr. Kelly O'Brien).

324 We thank all the interviewers, data collectors, research associates and coordinators, nurses and physicians
325 who provide support for data collection and extraction. The authors wish to thank the OCS staff for data
326 management, IT support, and study coordination: Lydia Makoroka, Lucia Light, Nahid Qureshi, Namita
327 Prabhu, Tsegaye Bekele, and Mustafa Karacam.

328 We also acknowledge the Public Health Laboratories, Public Health Ontario, for supporting record linkage
329 with the HIV viral load database.

330 The OHTN Cohort Study is supported by the Ontario Ministry of Health and Long-Term Care.

331 The opinions, results and conclusions are those of the authors and no endorsement by the Ontario HIV
332 Treatment Network or Public Health Ontario is intended or should be inferred.

333

334

335

336

References

337

- 338 1. The Ontario HIV Epidemiology and Surveillance Initiative. Current Trend for HIV in
339 Ontario: OHESI; 2023 [Available from: <https://www.ohesi.ca>].
- 340 2. Wilton J, Liu J, Sullivan A, Rachlis B, Marchand-Austin A, Giles M, et al. Trends in HIV
341 care cascade engagement among diagnosed people living with HIV in Ontario, Canada: A
342 retrospective, population-based cohort study. *PLoS One*. 2019;14(1):e0210096.
- 343 3. Rachlis B, Burchell AN, Gardner S, Light L, Raboud J, Antoniou T, et al. Social
344 determinants of health and retention in HIV care in a clinical cohort in Ontario, Canada. *AIDS*
345 *Care*. 2017;29(7):828-37.
- 346 4. Abebe Moges N, Olubukola A, Micheal O, Berhane Y. HIV patients retention and
347 attrition in care and their determinants in Ethiopia: a systematic review and meta-analysis. *BMC*
348 *Infect Dis*. 2020;20(1):439.
- 349 5. Benoit AC, Burchell AN, O'Brien KK, Raboud J, Gardner S, Light L, et al. Examining
350 the association between stress and antiretroviral therapy adherence among women living with
351 HIV in Toronto, Ontario. *HIV Res Clin Pract*. 2020;21(2-3):45-55.
- 352 6. Mbuagbaw L, Sivaramalingam B, Navarro T, Hobson N, Keepanasseril A, Wilczynski
353 NJ, et al. Interventions for enhancing adherence to antiretroviral therapy (ART): a systematic
354 review of high quality studies. *AIDS Patient Care and STDs*. 2015;29(5):248-66.
- 355 7. Mbuagbaw L, Hajizadeh A, Wang A, Mertz D, Lawson DO, Smieja M, et al. Overview
356 of systematic reviews on strategies to improve treatment initiation, adherence to antiretroviral
357 therapy and retention in care for people living with HIV: part 1. *BMJ Open*.
358 2020;10(9):e034793.
- 359 8. Yehia BR, Stephens-Shields AJ, Fleishman JA, Berry SA, Agwu AL, Metlay JP, et al.
360 The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression.
361 *PLOS One*. 2015;10(6):e0129376.
- 362 9. Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum:
363 updates, goals, and recommendations for the future. *AIDS Res Ther*. 2016;13:35.
- 364 10. Government of Ontario. Virtual Care 1: Comprehensive and Limited Virtual Care
365 Services 2022 [cited 2023 24th August 2023]. Available from:
366 [https://www.ontario.ca/document/education-and-prevention-committee-billing-briefs/virtual-](https://www.ontario.ca/document/education-and-prevention-committee-billing-briefs/virtual-care-1-comprehensive-and-limited#section-2)
367 [care-1-comprehensive-and-limited#section-2](https://www.ontario.ca/document/education-and-prevention-committee-billing-briefs/virtual-care-1-comprehensive-and-limited#section-2).
- 368 11. Heyworth L, Kirsh S, Zulman D, Ferguson JM, Kizer KW. Expanding access through
369 virtual care: The VA's early experience with Covid-19. *NEJM Catalyst Innovations in Care*
370 *Delivery*. 2020.
- 371 12. Government of Canada. Pan-Canadian virtual care priorities in response to COVID-19
372 2021.
- 373 13. Gomez T, Anaya YB, Shih KJ, Tarn DM. A Qualitative Study of Primary Care
374 Physicians' Experiences With Telemedicine During COVID-19. *The Journal of the American*
375 *Board of Family Medicine*. 2021;34(Supplement):S61-S70.
- 376 14. Glauser W. Virtual care is here to stay, but major challenges remain: *CMAJ*. *Canadian*
377 *Medical Association Journal*. 2020;192(30):E868-E9.
- 378 15. Government of Ontario. OHIP Info Bulletins. 2022.

- 379 16. Budak JZ, Scott JD, Dhanireddy S, Wood BR. The Impact of COVID-19 on HIV Care
380 Provided via Telemedicine-Past, Present, and Future. *Curr HIV/AIDS Rep.* 2021;18(2):98-104.
- 381 17. McGinnis KA, Skanderson M, Justice AC, Akgun KM, Tate JP, King JT, Jr., et al. HIV
382 care using differentiated service delivery during the COVID-19 pandemic: a nationwide cohort
383 study in the US Department of Veterans Affairs. *J Int AIDS Soc.* 2021;24 Suppl 6:e25810.
- 384 18. Dorn SD. Backslide or forward progress? Virtual care at U.S. healthcare systems beyond
385 the COVID-19 pandemic. *NPJ Digit Med.* 2021;4(1):6.
- 386 19. The Ontario HIV Treatment Network. HIV in Ontario 2023 [Available from:
387 <https://www.ohtn.on.ca>.
- 388 20. Ontario HIV treatment Network OCS (OHTN Cohort Study). Research Policies
389 [Available from: [https://ohtncohortstudy.ca/wp-content/uploads/2022/12/OCS-Research-](https://ohtncohortstudy.ca/wp-content/uploads/2022/12/OCS-Research-Policies_6-Oct-2022_Clean.pdf)
390 [Policies_6-Oct-2022_Clean.pdf](https://ohtncohortstudy.ca/wp-content/uploads/2022/12/OCS-Research-Policies_6-Oct-2022_Clean.pdf).
- 391 21. Rourke SB, Gardner S, Burchell AN, Raboud J, Rueda S, Bayoumi AM, et al. Cohort
392 profile: the Ontario HIV Treatment Network Cohort Study (OCS). *Int J Epidemiol.*
393 2013;42(2):402-11.
- 394 22. Lo Hog Tian JM, Watson JR, Deyman M, Tran B, Kerber P, Nanami K, et al. Building
395 capacity in quantitative research and data storytelling to enhance knowledge translation: a
396 training curriculum for peer researchers. *Research Involvement and Engagement.* 2022;8(1):69.
- 397 23. Cashman SB, Adeky S, Allen III AJ, Corburn J, Israel BA, Montañó J, et al. The power
398 and the promise: working with communities to analyze data, interpret findings, and get to
399 outcomes. *American Journal of Public Health.* 2008;98(8):1407-17.
- 400 24. Ding X, Abner EL, Schmitt FA, Crowley J, Goodman P, Kryscio RJ. Mental Component
401 Score (MCS) from Health-Related Quality of Life Predicts Incidence of Dementia in U.S. Males.
402 *J Prev Alzheimers Dis.* 2021;8(2):169-74.
- 403 25. Bush K, Kivlahan DR, McDonnell MB, Fihn SD, Bradley KA. The AUDIT alcohol
404 consumption questions (AUDIT-C): an effective brief screening test for problem drinking.
405 Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification
406 Test. *Arch Intern Med.* 1998;158(16):1789-95.
- 407 26. Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a brief
408 self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). *Journal*
409 *of Affective Disorders.* 2004;81(1):61-6.
- 410 27. Machado RC, Vargas HO, Baracat MM, Urbano MR, Verri Jr WA, Porcu M, et al. N-
411 acetylcysteine as an adjunctive treatment for smoking cessation: a randomized clinical trial.
412 *Brazilian Journal of Psychiatry.* 2020;42:519-26.
- 413 28. Etowa J, Hannan J, Babatunde S, Etowa EB, Mkandawire P, Phillips JC. HIV-related
414 stigma among black mothers in two north American and one African cities. *Journal of Racial and*
415 *Ethnic Health Disparities.* 2020;7:1130-9.
- 416 29. Cote J, Godin G, Ramirez-Garcia P, Rouleau G, Bourbonnais A, Gueheneuc YG, et al.
417 Virtual intervention to support self-management of antiretroviral therapy among people living
418 with HIV. *J Med Internet Res.* 2015;17(1):e6.
- 419 30. Bridge PD, Sawilowsky SS. Increasing physicians' awareness of the impact of statistics
420 on research outcomes: comparative power of the t-test and Wilcoxon rank-sum test in small
421 samples applied research. *Journal of Clinical Epidemiology.* 1999;52(3):229-35.
- 422 31. Logie C, James L, Tharao W, Loutfy M. Associations between HIV-related stigma, racial
423 discrimination, gender discrimination, and depression among HIV-positive African, Caribbean,
424 and Black women in Ontario, Canada. *AIDS patient care and STDs.* 2013;27(2):114-22.

- 425 32. Burchell AN, Gardner S, Light L, Ellis BM, Antoniou T, Bacon J, et al. Implementation
426 and operational research: engagement in HIV care among persons enrolled in a clinical HIV
427 cohort in Ontario, Canada, 2001–2011. *JAIDS Journal of Acquired Immune Deficiency*
428 *Syndromes*. 2015;70(1):e10-e9.
- 429 33. Heymans MaE I. *Applied missing data analysis with SPSS and (R) Studio*. Heymans and
430 Eekhout;2019.
- 431 34. Van Buuren S. *Flexible imputation of missing data*: CRC press; 2018.
- 432 35. Ferguson JM, Jacobs J, Yefimova M, Greene L, Heyworth L, Zulman DM. Virtual care
433 expansion in the Veterans Health Administration during the COVID-19 pandemic: clinical
434 services and patient characteristics associated with utilization. *J Am Med Inform Assoc*.
435 2021;28(3):453-62.
- 436 36. Realize. *Fostering positive change for people living with HIV and other episodic*
437 *disabilities..* 2023 [Available from: <http://forum.realizecanada.org/about-us/>].
- 438 37. Lawal FJ, Omotayo MO, Lee TJ, Srinivasa Rao ASR, Vazquez JA. HIV Treatment
439 Outcomes in Rural Georgia Using Telemedicine. *Open Forum Infect Dis*. 2021;8(6):ofab234.
- 440 38. León A, Cáceres C, Fernández E, Chausa P, Martín M, Codina C, et al. A new
441 multidisciplinary home care telemedicine system to monitor stable chronic human
442 immunodeficiency virus-infected patients: a randomized study. *PLoS One*. 2011;6(1):e14515.
443

444 **Supporting information**

445 **S 1 Fig.** Study flow diagram of participants who received HIV care in 2022.

446 **S 1 Table.** Multivariable subgroup regression analysis of HIV-related outcomes of people receiving care
447 in Ontario, Canada

448




Fig 1. Study flow diagram of participants who received HIV care in 2022.

Figure